BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23334362)

  • 21. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
    Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
    Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia.
    Mousavian Z; Nowzari-Dalini A; Rahmatallah Y; Masoudi-Nejad A
    Mol Med; 2019 Aug; 25(1):36. PubMed ID: 31370801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapsed infant MLL-rearranged acute lymphoblastic leukemia with additional genetic alterations.
    Ishida H; Kanamitsu K; Washio K; Muraoka M; Sakakibara K; Matsubara T; Kanzaki H; Shimada A
    Pediatr Blood Cancer; 2016 Nov; 63(11):2059-60. PubMed ID: 27322816
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?
    Mansur MB; Ford AM; Emerenciano M
    Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):521-526. PubMed ID: 29056538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trametinib inhibits
    Kerstjens M; Pinhancos SS; Castro PG; Schneider P; Wander P; Pieters R; Stam RW
    Haematologica; 2018 Apr; 103(4):e147-e150. PubMed ID: 29419436
    [No Abstract]   [Full Text] [Related]  

  • 26. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
    Brown P; Levis M; McIntyre E; Griesemer M; Small D
    Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
    Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia.
    Chowdhury T; Brady HJ
    Blood Cells Mol Dis; 2008; 40(2):192-9. PubMed ID: 17905612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of NG2 antigen in MLL-rearranged acute leukemias: how complex does it get?
    Menendez P; Bueno C
    Leuk Res; 2011 Aug; 35(8):989-90. PubMed ID: 21492935
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Schneider P; de Lorenzo P; Valsecchi MG; den Boer ML; Pieters R
    Blood; 2007 Oct; 110(7):2774-5. PubMed ID: 17881645
    [No Abstract]   [Full Text] [Related]  

  • 33. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement.
    Bardini M; Woll PS; Corral L; Luc S; Wittmann L; Ma Z; Lo Nigro L; Basso G; Biondi A; Cazzaniga G; Jacobsen SE
    Leukemia; 2015 Jan; 29(1):38-50. PubMed ID: 24798483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
    Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics.
    Candelli T; Schneider P; Garrido Castro P; Jones LA; Bodewes E; Rockx-Brouwer D; Pieters R; Holstege FCP; Margaritis T; Stam RW
    Leukemia; 2022 Jan; 36(1):58-67. PubMed ID: 34304246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements.
    Nishi M; Eguchi-Ishimae M; Wu Z; Gao W; Iwabuki H; Kawakami S; Tauchi H; Inukai T; Sugita K; Hamasaki Y; Ishii E; Eguchi M
    Leukemia; 2013 Feb; 27(2):389-97. PubMed ID: 22918121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.
    Stam RW; Hubeek I; den Boer ML; Buijs-Gladdines JG; Creutzig U; Kaspers GJ; Pieters R
    Leukemia; 2006 Jan; 20(1):179-82. PubMed ID: 16307022
    [No Abstract]   [Full Text] [Related]  

  • 38. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
    Stumpel DJ; Schneider P; van Roon EH; Boer JM; de Lorenzo P; Valsecchi MG; de Menezes RX; Pieters R; Stam RW
    Blood; 2009 Dec; 114(27):5490-8. PubMed ID: 19855078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
    Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
    Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.